Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at D. Boral Capital from $12.00 to $1.00. They now have a "buy" rating on the stock.
Carisma Therapeutics Provides Corporate Updates [Yahoo! Finance]
Carisma Therapeutics Provides Corporate Updates
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]